ABSTRACT – Introduction: The vulvar area may be affected by many noninfectious conditions with similar clinical appearance, requiring a cutaneous biopsy. Our goal was to characterize the noninfectious vulvar diseases that required a biopsy in a southwestern Europe Central Hospital during a 10-year period.

Methods: A retrospective study of all the noninfectious vulvar diseases with histological confirmation diagnosed in our institution was conducted between January 1, 2008 and December 31, 2017.

Results: The sample included a total of 323 biopsies from 317 patients, aged between 11 and 98 years (mean age of 54.2 years). A total of 36 vulvar diseases was identified. Neoplastic conditions were the most frequently found, particularly melanotic macules (22.3%). The most frequent malignant tumor was vulvar intraepithelial neoplasia (6.2%) and squamous cell carcinoma (5.6%). The most common dermatosis was lichen sclerosus (12.7%).

Conclusion: Neoplasms were the most frequently diagnosed conditions affecting the vulvar area that required a biopsy. Ruling out malignancy was also the main reason to perform a biopsy. This study highlights the variety of noninfectious diseases that may affect the vulva and require a biopsy. Since vulvar diseases may be serious and carry high levels of patient distress a correct understanding of these conditions is crucial.

KEYWORDS – Biopsy; Vulvar Diseases; Vulvar Lichen Sclerosus; Vulvar Neoplasms.

INTRODUCTION

Cutaneous lesions of the vulva are common and may be associated with considerable physical and psychological distress. There is a tendency to attribute an infectious or venereal origin to any vulvar lesion, which contributes to significant anxiety. However, the vulva may be site of noninfectious lesions including widespread dermatoses which may have distinct or atypical presentations in this anatomic area (like psoriasis or lichen planus), other clinical entities that occur only in the genital area (such as Zoon vulvitis), as well as benign and malignant neoplasms. Therefore, its identification is challenging, and a cutaneous biopsy may be required for the correct diagnosis.

To date, only a few studies have reviewed the relative frequencies of biopsy-proven vulvar diseases.

The objective of our study was to assess all cases of noninfectious vulvar diseases that required a biopsy over a 10-year period in a tertiary hospital, including its relative frequencies, treatment, and clinical evolution.

MATERIAL AND METHODS

A retrospective study of all noninfectious vulvar diseases with histological confirmation diagnosed in Centro Hospitalar e Universitário...
Lisboa Norte, in Lisbon, Portugal, during a 10-year period was conducted. The histopathology archive was searched for all the vulvar biopsies received between January 1, 2008 and December 31, 2017 (a total of 403 biopsies). The clinical files were then reviewed and all cases of noninfectious diseases with histological diagnosis and clinical information were included. The exclusion criteria were infectious diseases (22), noninfectious diseases without clinical information (11), nonspecific features on histopathology (30) and repeated biopsies of the same patient addressing the same pathological process (17).

The diseases were classified in two main types (inflammatory and neoplastic), considering the pathological findings. Treatment and clinical evolution of the most frequent conditions was examined. Results were analyzed by SPSS Statistics 25® software. Informed consent was obtained from the patients.

RESULTS

A total of 323 biopsies from 317 patients were included. The age of the patients ranged from 11 to 98 years, with a mean of 54.2 years ($\sigma=19$). A total of 36 vulvar conditions was identified (21 neoplastic and 15 inflammatory). Neoplasms were present in approximately 68% of the patients (219/323) and inflammatory dermatoses in 32% (104/323) [Tables 1 and 2]. Overall, the most common identified condition was melanotic macule (22.3%, 72/323), followed by lichen sclerosus (LS) (12.7%, 41/323).

Prevalence of neoplasms

Neoplasms were mainly benign tumors (76.3%, 163/219), particularly melanotic macules (44.2%, 72/163) and melanocytic nevi (20.2%, 33/163). Amongst these, the most common were intradermal nevi (42.4%, 14/33), followed by dysplastic nevi (21.2%, 7/33) and compound nevi (8.2%, 6/33). The remaining patients had other benign tumors such as seborrheic keratosis (8.6%, 14/163), epidermoid cysts, fibromas (6.1%, 10/163 each), hidrocystomas (4.9%, 8/163) and other even less frequent lesions (Table 1).

Amongst the malignant tumors (23.7%, 52/219), the most frequent was vulvar intraepithelial neoplasia (VIN), corresponding to 38.5% (38.5%, 20/52). Of these, 11 cases were associated with Human Papillomavirus (HPV) infection and thus classified as usual-type

Table 1 - Vulvar neoplasms.

| Subtypes                          | Number | % T (N)* | Age (years; x(±σ)) |
|-----------------------------------|--------|----------|--------------------|
| **In situ vulvar carcinoma**      | 20     | 6.2 (9.1)| 57 (±15)           |
| uVIN                              | 11     | 3.4 (5)  | 52 (±10)           |
| dVIN                              | 9      | 2.8 (4.1)| 65 (±16)           |
| **Squamous cell carcinoma**       | 18     | 5.6 (8.2)| 70 (±16)           |
| **Basal cell carcinoma**          | 7      | 2.2 (3.2)| 75 (±10)           |
| **Paget disease of the vulva**    | 4      | 1.2 (1.8)| 66 (±4)            |
| **Melanoma**                      | 2      | 0.6 (0.9)| 63 (±24)           |
| **Kaposi sarcoma**                | 1      | 0.3 (0.5)| 31                 |
| **Sub total**                     | 52     | 16.1 (23.7)| 64 (±16)        |
| **Melanotic macule**              | 72     | 22.3 (32.9)| 52 (±16)       |
| **Melanocytic nevi**              | 33     | 10.2 (15.1)| 35 (±15)       |
| **Seborrheic keratosis**          | 14     | 4.3 (6.4)| 62 (±19)           |
| **Epidermoid cyst**               | 10     | 3.1 (4.6)| 58 (±15)           |
| **Fibromas**                      | 10     | 3.1 (4.6)| 43 (±19)           |
| **Hidrocystoma**                  | 8      | 2.5 (3.6)| 54 (±23)           |
| **Hidradenoma papilliferum**      | 6      | 1.9 (2.7)| 52 (±20)           |
| **Angiokeratoma**                 | 4      | 1.2 (1.8)| 67 (±11)           |
| **Steatocystoma**                 | 3      | 0.9 (1.4)| 69 (±37)           |
| **Hemangioma**                    | 2      | 0.6 (0.9)| 52 (±1)            |
| **Fibrous histiocytoma**          | 1      | 0.3 (0.5)| 31                 |
| **Granular cell tumor**           | 1      | 0.3 (0.5)| 71                 |
| **Venous lake**                   | 1      | 0.3 (0.5)| 55                 |
| **Mucous cyst**                   | 1      | 0.3 (0.5)| 48                 |
| **Poroma**                        | 1      | 0.3 (0.5)| 58                 |
| **Sub total**                     | 167    | 51.7 (76.3)| 50 (±18)      |
| **Total of neoplastic diseases**  | 219    | 67.8 (100)| 54 (±19)       |

* T – Percentage in the total of the identified vulvar conditions; N – Relative proportion considering the group of neoplasms
VIN (uVIN), while the other 9 cases corresponded to differentiated vulvar intraepithelial neoplasia (dVIN) and were linked to chronic inflammatory conditions. The second most common malignant neoplasm was invasive squamous cell carcinoma (SCC) (34.6%, 18/52). There were seven cases of basal cell carcinoma (BCC) (13.5%, 7/52), three cases of Paget’s disease of the vulva (PDV) (5.8%, 3/52) and two cases of malignant melanoma (3.8%, 2/52). Kaposi sarcoma was diagnosed in only one patient (1.9%, 1/52).

Prevalence of inflammatory dermatoses

The most frequent inflammatory condition was LS (39.4%, 41/104), followed by lichen simplex chronicus (20.2%, 21/104), eczematous dermatitis (Fig. 2b) and ulcer not otherwise specified (NOS) (6.7%, 7/104 each) and Zoon vulvitis (4.8%, 5/104). Less frequent dermatoses included psoriasis, lichen planus, ruptured cyst, Behçet disease, post-inflammatory hyperpigmentation (2.9%, 3/104 each), Fordyce disease and radiodermatitis (1.9%, 2/104). There was just one case of fixed drug eruption and one case of bullous pemphigoid.

Table 2 - Vulvar inflammatory dermatoses.

| Subtypes                          | Number | % T (N)* | Age (years; x(st)) |
|----------------------------------|--------|----------|--------------------|
| Lichen sclerosus                 | 41     | 12.7 (39.4) | 63(±15)            |
| Lichen simplex chronicus         | 21     | 6.5 (20.2) | 55(±24)            |
| Contact dermatitis               | 7      | 2.2 (6.7)  | 53(±19)            |
| Ulcer not otherwise specified    | 7      | 2.2 (6.7)  | 51(±26)            |
| Zoon vulvitis                    | 5      | 1.5 (4.8)  | 55(±15)            |
| Psoriasis                        | 3      | 0.9 (2.9)  | 42(±15)            |
| Lichen planus                    | 3      | 0.9 (2.9)  | 60(±24)            |
| Ruptured cyst                    | 3      | 0.9 (2.9)  | 44(±15)            |
| Behçet disease                   | 3      | 0.9 (2.9)  | 35(±27)            |
| Post-inflammatory hyperpigmentation| 3     | 0.9 (2.9)  | 47(±2)             |
| Radiation dermatitis             | 2      | 0.6 (1.9)  | 76(±7)             |
| Fordyce disease                  | 2      | 0.6 (1.9)  | 45(±35)            |
| Non-specific vulvitis            | 2      | 0.6 (1.9)  | 56(±30)            |
| Fixed drug eruption              | 1      | 0.3 (1.0)  | 43                 |
| Bullous pemphigoid               | 1      | 0.3 (1.0)  | 98                 |
| Total of inflammatory dermatoses | 104    | 32.2 (100) | 57(±20)            |

* T – Percentage in the total of the identified vulvar conditions; I – Percentage considering the group of inflammatory condition.

DISCUSSION

The aim of this retrospective study was to evaluate which vulvar diseases required a biopsy in our Dermatology department. As expected, most of these cases are of neoplastic etiology.

Amongst neoplasms, benign tumors (76.3%, 163/219) were by...
Table 3 - Applied treatments and clinical outcomes.

| Vulvar diseases | N  | Treatment                                                                 | Clinical outcome (follow-up period: 2 to 10 years) |
|-----------------|----|---------------------------------------------------------------------------|----------------------------------------------------|
| **Benign**      |    | All benign tumors were excised with the following exceptions:              | No relapses nor clinical progression                |
|                 | 167| • 6 cases of melanocytic macules, 4 non-dysplastic melanocytic nevi        |                                                    |
|                 |    | • 1 hemangioma: clinical surveillance                                       |                                                    |
|                 |    | • One angiokeratoma: CO2 laser therapy                                      |                                                    |
| **VIN**         | 20 | • 14 cases: CO2 laser therapy                                               | Complete remission in 12 patients; 2 relapses with invasive SCC (vulvectomy was performed) |
|                 |    | • 4 cases: wide local excision                                              | No relapses                                        |
|                 |    | • 2 cases: cryotherapy and imiquimod                                        | No relapses                                        |
| **SCC**         | 18 | • 10 cases: bilateral vulvectomy                                             | 1 relapse after 3 months                          |
|                 |    | • 3 cases: with unilateral vulvectomy                                        | 1 relapse after 10 months                         |
|                 |    | • 3 cases: wide local excision                                              | 1 relapse after 3 years                           |
|                 |    | • 2 cases of distant disease: palliative care (radiotherapy and chemotherapy)| 1 patient died within a year; 1 patient with decreased tumor size (died 3 years later from other causes) |
| **BCC**         | 7  | • 4 cases: local excision                                                   | No relapses                                        |
|                 |    | • 2 cases: bilateral vulvectomy                                              | No relapses                                        |
|                 |    | One superficial BCC: CO2 laser therapy                                       | Relapse was documented after 6 months and a wide local excision was performed |
| **PDV**         | 4  | All of them received multiple therapies. 3 cases: CO2 laser and/or PDT, One patient: multiple surgical interventions (including total vulvectomy) and radiotherapy | Several relapses. Disease control was achieved with topical imiquimod in all cases (follow-up of 3 to 5 years) |
| **MM**          | 2  | Diagnosed stage IA and IB: unilateral vulvectomy                            | No relapses (follow-up period of 5 and 6 years)    |
| **KS**          | 1  | HIV-associated: treated with antiretroviral therapy                          | Clinical resolution                                 |

**Dermatoses**

| Vulvar diseases | N  | Treatment                                                                 | Clinical outcome                                           |
|-----------------|----|---------------------------------------------------------------------------|-----------------------------------------------------------|
| **LS**          | 41 | High potency topical steroids (dlobetasol ointment) One patient had concomitant VIN: CO2 laser therapy | No documented cases of SCC during the follow-up            |
| **Lichen simplex chronicus & eczematous dermatitis** | 28 | Moderate to high potency topical steroids and emollients                   | Good clinical response                                     |
| **Ulcer NOS**   | 7  | Topical fusidic acid and low potency topical steroids                       | Clinical remission in one to two weeks                     |
| **Zoon vulvitis** | 5  | Moderate potency topical steroids, emollients, general measures            | Disease control was achieved                               |
| **Psoriasis**   | 3  | Low potency topical steroids alone or in conjunction with topical tacalcitol| In two patients skin lesions progressed to other body areas|
| **Lichen planus** | 3  | High potency topical steroids                                               | All cases presented with only vulvar involvement; one patient developed oral disease |

**Neoplasms**

**Benign tumors**

Vulvar diseases that Required a Biopsy: A Retrospective Study; Rita Bouceiro-Mendes, M. Mendonça-Sanches, Luís Soares-de-Almeida, Isabel Correia-Fonseca, João Borges-da-Costa

far the most frequent. Vulvar malignant neoplasms are relatively uncommon (0.4% of all cancers) with an overall incidence of 2-7 cases per 100 000 women. Their incidence increases with age with a median age at diagnosis between 60-70 years. In our study median age at diagnosis was 64 years.

**Vulvar neoplasms**

Most frequently biopsied benign vulvar neoplasms

The most frequently biopsied benign tumors were melanocytic macules (44.2%, 72/163) and melanocytic nevi (20.2%, 33/163). Benign tumors were mainly biopsied to rule out malignancy.

Melanocytic macules (Fig. 1), the most frequently encountered, are common benign pigmented lesions of small size located on labia minora that follow a benign clinical course. In our study, melanocytic macules represented almost 60% of the pigmented vulvar lesions (versus 68% in other studies). They are more commonly found among perimenopausal women (median age of 43 years). Our patients were older, with a median age of 52 years.

Melanocytic macules, particularly with a bigger size, can be clinically indistinguishable from melanoma, thus requiring a skin biopsy.

According to the literature, melanocytic nevi account for 23% of all pigmented vulvar lesions, which is consistent with our results (25% of the identified pigmented lesions). In contrast to melanocytic macules, vulvar nevi are generally encountered in premenopausal women, with a median age of 30 to 34 years (in our study median age was 35 years). Common nevi are well demarcated, with regular borders, uniform pigmentation, and typically small size (<1 cm in diameter). The main reason for biopsy is to differentiate from melanoma.

Seborrheic keratoses, the third most common biopsied benign neoplasm, become more prevalent in increasing age (we found a median age at diagnosis of 62 years). Their clinical appearance may resemble melanoma and thus require a biopsy.

Most frequently biopsied malignant vulvar neoplasms

Taken together, VIN and invasive SCC (Fig. 2), are by far the most common vulvar malignancy (83% to 90%, in most
SCC arises from two major types of VIN, which correspond to two distinct oncogenic pathways: uVIN is HPV-dependent (and is more common in younger women) while dVIN develops independently of HPV infection and accounts for 20% of all cases of SCC occurring in post-menopausal women within a background of chronic inflammatory dermatosis, most frequently LS. First-line treatment for SCC is excision with or without sentinel lymph node dissection. Treatment for disseminated disease is usually palliative. On the other hand, VIN may be treated conservatively with topical imiquimod, photodynamic therapy and laser therapy. VIN usually manifests as an asymptomatic and solitary pink or red scaly plaque with irregular edges. Recurrence rates for vulvar invasive SCC are high (12% to 39%) and regular surveillance is recommended. In our study, VIN and SCC corresponded to 73.1% (38/52) of all malignant neoplasms which is slightly inferior to previously reported data.
the two patients with distant disease who received palliative care, there was a recurrence rate of 18.8% (3/16), consistent with the literature. The preferred treatment for VIN was CO₂ laser therapy with a success rate of 78.6%, identical to other studies.

In our series, BCC was the third most commonly biopsied malignant neoplasm, corresponding to 13.5% (7/52) which differs from previously reported prevalence rates of only 1%-4%. Average age at diagnosis was 75 years, consistent with other studies (average age of 68-73 years). Vulvar BCCs usually present as single lesions in labia minora and majora. Metastatic potential is low but local recurrence rates are high (up to 20%).

Paget’s disease of the vulva (Fig. 3) accounted for 1.8% of the vulvar malignancies, with an average age of 66 years, consistent with the literature. Regardless of the adopted therapy, all four cases of PDV had a chronic course. Partial disease remission was possible under local therapy with imiquimod. High recurrence rates are typical, and overtreatment should be avoided.

In our series melanoma accounted for only 0.9% (2/52) of malignant neoplasms which is inferior to the 3%-10% reported rates. It is more common in postmenopausal women.

Inflammatory dermatoses

Vulvar dermatoses were mainly biopsied to rule out malignancy, but some lesions of long duration with a doubtful clinical diagnosis were also biopsied for diagnostic purposes.

As reported in the literature, vulvar LS was the most commonly biopsied dermatosis (39.4%, 41/104) and the second most common of all the identified conditions (12.7%, 41/323). LS is a chronic inflammatory skin disease with a predilection for the external genitalia. It is more prevalent in women, especially after menopause, although it can develop at any age. Typical presentation consists of a well-defined white sclerotic plaque with an atrophic wrinkled surface (Fig. 4). Associated symptoms include pruritus, dyspareunia, burning, bleeding, and dysuria. If left untreated, it may lead to scarring and permanent distortion of the vulvar structure. Furthermore, untreated lesions carry a 2%-6% risk of vulvar SCC.

Ultra-potent topical steroids are the mainstay of treatment and even asymptomatic women should be treated. Long-term maintenance treatment arrests disease progression and reduces the likelihood to develop SCC. In our institution LS cases were biopsied mainly to rule out associated malignancy.

Lichen simplex chronicus is one of the most common causes of vulvar itching. When considering vulvar dermatoses, previous studies reported a similar prevalence of 20%. It is caused by persistent itching and scratching which leads to epidermal thickening and lichenification. Vulvar contact dermatitis, on the other hand, is generally caused by repeated contact with an irritant (irritant contact dermatitis).
The lesions are typically limited to the site of contact (Fig. 5A). None of these conditions requires a biopsy except when the diagnosis is not straightforward. A bland skin care regimen and moderate-potent topical steroids are advised.6,22

The three patients with ulcers NOS had only genital lesions and associated infection was excluded. These lesions present as well-circumscribed round to oval ulcers usually measuring less than 3 cm (Fig. 5B), affecting mainly the vulvar mucous membrane.5,11,15 The reason to biopsy was to exclude malignancy.

For Zoon vulvitis we found an overall prevalence of 1.5%. Zoon vulvitis is a relatively rare pathology.2,15,27 It is a benign and chronic condition with unknown etiology that tends to affect postmenopausal women (mean age at diagnosis was 55 years). It may be asymptomatic, but it is frequently associated with itching, burning, pain and bleeding. Lesions present as well-defined erythematous or brownish-orange plaques with bilateral and symmetrical distribution (Fig. 6) and can be confused with VIN.24 Biopsy is essential for diagnosis.23

Study limitations

Adding to the fact that this was a retrospective study, the other main limitation of our work relies on the fact that only conditions with a histological confirmation were enrolled. As such, other clinically diagnosed noninfectious vulvar diseases were excluded.

CONCLUSION

In this study, neoplastic conditions were the most frequently biopsied lesions affecting the vulvar area, with VIN and SCC as the most documented malignant tumors. Concerning the inflammatory dermatoses, LS was by far the most prevalent. These results highlight the main reason to biopsy, which was to exclude malignant processes. Diagnosis of vulvar noninfectious inflammatory lesions is usually made on clinical criteria.

From a practical approach, this study shows that when facing a vulvar pigmented lesion that warrants a biopsy, it will most likely be a benign lesion. On the other hand, if we are facing a red and eroded plaque, there is a considerable likelihood of VIN. Vulvar ulcerations that develop in a background of inflammation or are refractory to treatment and thus require a biopsy carry a high probability of SCC. This study also illustrates the myriad of conditions that may affect the vulva. These conditions cause a considerable burden on the patients and some of them have serious health consequences if left untreated. Correct diagnosis and management are thus essential.

Acknowledgments /Agradecimentos

The authors thank Dr. Marta Aguado Lobo and Dr. Pablo Espinosa Lara for their contribution in the acquisition of the histological pictures included in this article.

Presentations /Apresentações

Part of the content for this article was presented as an oral communication in the XIX Congresso Nacional de Dermatologia e Venereologia, Sheraton Porto Hotel, Porto, December 6th 8th 2019

Conflicts of Interest: The authors have no conflicts of interest to declare. Financing support: This work has not received any contribution, grant or scholarship. Confidentiality of Data: The authors declare that they have followed the protocols of their work center on the publication of data from patients. Protection of Human and Animal Subjects: The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki). Provenance and Peer Review: Not commissioned; externally peer reviewed.

Conflitos de Interesse: Os autores declararam a inexistência de conflitos de interesse na realização do presente trabalho. Fontes de Financiamento: Não existiram fontes externas de financiamento para a realização deste artigo. Confidencialidade dos Dados: Os autores declararam ter seguido os protocolos da sua instituição acerca da publicação dos dados de doentes. Proteção de Pessoas e Animais: Os autores declararam que os procedimentos seguidos estavam de acordo com os regulamentos estabelecidos pelos responsáveis da Comissão de Investigação Clínica e Ética e de acordo com a Declaração de Helsinki da As sociação Médica Mundial. Proveniência e Revisão por Pares: Não comissionado; revisão externa por pares.
REFERENCES

1. Singh G, Rathore BS, Bhardwaj A, Sharma C. Non venereal dermatoses of vulva in sexually active women: a clinical study. Int J Res Dermatol. 2016;2:25-9.

2. Andreassi L, Bilenchi R. Non-infectious inflammatory genital lesions. Clin Dermatol. 2014;32:307-14. doi: 10.1016/j.clindermatol.2013.08.015.

3. Nyati A, Agarwal P. Pattern of non-venereal dermatoses of female external genitalia in Rajasthan. Asian Pac J Health Sci. 2016;3:249-65.

4. Yura E, Flury S. Cutaneous lesions of the external genitalia. Med Clin North Am. 2018;102:279-300. doi: 10.1016/j.mcna.2017.10.012.

5. Barchino-Ortiz L, Suárez-Fernández R, Lázaro-Ochaita P. Vulvar inflammatory dermatoses. Actas Dermo-Sifiliogr. 2012;103:260-75. doi: 10.1016/j.ad.2011.08.001.

6. Stockdale CK, Boardman L. Diagnosis and treatment of vulvar dermatoses. Obstet Gynecol. 2018;131:371-86. doi: 10.1097/AOG.0000000000002460.

7. Chan MP, Zimarowski MJ. Vulvar dermatoses: a histopathologic review and classification of 183 cases. J Cutan Pathol. 2015;42:510-8. doi: 10.1111/cup.12541.

8. O'keefe RJ, Scurry JP, Dennersten G, Sfameni S, Brenan J. Audit of 114 non-neoplastic vulvar biopsies. BJOG. 1995;102:780-6.

9. Weinberg D, Gomez-Martinez RA. Vulvar cancer. Obstet Gynecol Clin North Am. 2019;46:125-35. doi: 10.1016/j.ogc.2018.09.008.

10. Chokoeva AA, Tchernev G, Castelli E, Orlando E, Verma SB, Grebe M, et al. Vulvar cancer: a review for dermatologists. Wien Med Wochenschr. 2015;165:164-77. doi: 10.1007/s10354-015-0354-9.

11. Matthews N, Wang V, Brooks J, Koumouzakis G. Genital diseases in the mature woman. Clin Dermatol. 2018;36:208-21. doi: 10.1016/j.clindermatol.2017.10.012.

12. Allbritton JI. Vulvar neoplasms, benign and malignant. Obstet Gynecol Clin North Am. 2017;44:339-52. doi: 10.1016/j.ogc.2017.04.002.

13. Muraklu EC, Penn LA, Hale CS, Pomeranz MK, Polsky D. Vulvar nevi, melanosis, and melanoma: An epidemiologic, clinical, and histopathologic review. J Am Acad Dermatol. 2014;71:1241-9. doi: 10.1016/j.jaad.2014.08.019.

14. Hoang LN, Park KJ, Seo CW, Murray R. Squamous precursor lesions of the vulva: current classification and diagnostic challenges. Pathology. 2016;48:291-302. doi: 10.1016/j.pan.2016.02.015.

15. Sathy MA, Hoang MP. A Histologic review of vulvar inflammatory dermatoses and intraepithelial neoplasia. Dermatol Clin. 2010;28:649-67. doi: 10.1016/j.det.2010.07.005.

16. Singh N, Gilks CB. Vulval squamous cell carcinoma and its precursors. Histopathology. 2017;70:127-38. doi: 10.1111/his.13989.

17. Satmary W, Holschneider CH, Brunette LL, Natarajan S. Vulvar intraepithelial neoplasia: Risk factors for recurrence. Gynecol Oncol. 2018;148:126-31. doi: 10.1016/j.ygyno.2017.10.029.

18. Bouceiro-Mendes R, Mendonça-Sanches M, Soares-de-Almeida L, Correia-Fonseca I. A case of chronic and relapsing Paget disease of the vulva. Rev Bras Ginecol Obstet. 2019;41:412-6. doi: 10.1055/s-0039-1687861.

19. Guerrero A, Venkatesan A. Inflammatory vulvar dermatoses. Clin Obstet Gynecol. 2015;58:464-75. doi: 10.1097/GRF.0000000000000125.

20. Lee A, Fischer G. Diagnosis and treatment of vulvar lichen sclerosus: an update for dermatologists. Am J Clin Dermatol. 2018;19:695-706. doi: 10.1007/s40257-018-0364-7.

21. Pérez-López FR, Vieria-Baptista P. Lichen sclerosus in women: a review. Climacteric. 2017;20:339-47. doi: 10.1080/13697137.2017.1343295.

22. Sand FL, Thomsen SF. Skin diseases of the vulva: eczematous diseases and contact urticaria. J Obstet Gynecol. 2018;38:295-300. doi: 10.1080/01443615.2017.1329283.

23. Simonette C, Burns EK, Guo MA. Vulvar dermatoses: a review and update. Ma Med. 2015;112:301-7.

24. Mauskar MM, Marathe K, Venkatesan A, Schlosser BJ, Edwards L. Vulvar diseases: Conditions in adults and children. J Am Acad Dermatol. 2020;82:1287-98. doi: 10.1016/j.jaad.2019.10.077.